FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children

Key Takeaways Sanofi seeks FDA approval to expand Tzield use to children aged one and older with stage 2 T1D.SNY's filing received priority review, with an FDA decision expected by April 29, 2026.The application is backed by interim phase IV PETITE-T1D data in children under eight.Sanofi (SNY) announced that the FDA has accepted a regulatory filing seeking to expand the use of its type 1 diabetes (T1D) drug, Tzield (teplizumab), in individuals aged one year and older. The agency has granted priority review ...